Infant HIV diagnosis and turn-around time for testing in Malawi, 2015

African Journal of Laboratory Medicine

 
 
Field Value
 
Title Infant HIV diagnosis and turn-around time for testing in Malawi, 2015
 
Creator Ali, Hammad Minchella, Peter Chipungu, Geoffrey Kim, Evelyn Kandulu, James Midiani, Dalitso Kim, Andrea Swaminathan, Mahesh Gutreuter, Steve Nkengasong, John Singer, Daniel
 
Subject — HIV; Malawi; infant HIV testing; turn-around time
Description Background: For HIV-exposed infants in Malawi, there are missed opportunities at each step of the testing and treatment cascade.Objective: This study assessed factors associated with HIV positivity among infants in Malawi and turn-around times for infant HIV testing.Methods: HIV testing data for infants aged 0–18 months from 2012 to 2015 were extracted from the Malawi HIV laboratory information management system and analysed using logistic regression. Turn-around time was defined as time between collection of samples to results dispatch from the laboratory.Results: A total of 106 997 tests were included in the analyses. A subset of 76 006 observations with complete dates were included in the turn-around time analysis. Overall positivity was 4.2%. Factors associated with positivity were increasing age (infants aged 3–6 months: adjusted odds ratio [aOR] = 2.24; infants aged 6–9 months: aOR = 3.42; infants aged 9 months: aOR = 4.24), female sex (aOR = 1.08) and whether the mother was alive and not on antiretroviral therapy at time of the infant’s test (aOR = 1.57). Provision of HIV prophylaxis to the infant after birth (aOR = 0.38) was found to be protective against HIV positivity. The median turn-around time was 24 days (increased from 19 to 34 days between 2012 and 2015).Conclusion: Infant HIV positivity has decreased in Malawi, whereas turn-around time has increased. Factors associated with positivity include increasing age, female sex, and whether the mother was alive and not on antiretroviral therapy at the time of the infant’s test.
 
Publisher AOSIS
 
Contributor This study was supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC).
Date 2020-11-26
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — —
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/ajlm.v9i1.904
 
Source African Journal of Laboratory Medicine; Vol 9, No 1 (2020); 7 pages 2225-2010 2225-2002
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://ajlmonline.org/index.php/ajlm/article/view/904/1743 https://ajlmonline.org/index.php/ajlm/article/view/904/1742 https://ajlmonline.org/index.php/ajlm/article/view/904/1744 https://ajlmonline.org/index.php/ajlm/article/view/904/1741
 
Coverage — — —
Rights Copyright (c) 2020 Hammad Ali, Peter Minchella, Geoffrey Chipungu, Evelyn Kim, James Kandulu, Dalitso Midiani, Andrea Kim, Mahesh Swaminathan, Steve Gutreuter, John Nkengasong, Daniel Singer https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT